Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Carcinoma, Transitional Cell 14Urinary Bladder Neoplasms 11Breast Neoplasms 11Neoplasm Metastasis 10Carcinoma, Renal Cell 8Carcinoma, Merkel Cell 8Neoplasms 7Colorectal Neoplasms 7Head and Neck Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Neuroendocrine Tumors 4Leukemia, Myeloid, Acute 4Urethral Neoplasms 3Ureteral Neoplasms 3Skin Neoplasms 3Prostatic Neoplasms 3Glioblastoma 3Endometrial Neoplasms 3Colonic Neoplasms 3Carcinoma, Neuroendocrine 3Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Sarcoma 2Penile Neoplasms 2Pancreatic Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasm, Residual 2Mesothelioma, Malignant 2

Interventions

Cyclophosphamide 297Rituximab 272Etoposide 149Filgrastim 142fludarabine phosphate 120Cytarabine 109Vincristine 107Melphalan 102Radiotherapy 101Doxorubicin 97Peripheral Blood Stem Cell Transplantation 93Methotrexate 91fludarabine 86Prednisone 86Busulfan 86Tacrolimus 66Mycophenolic Acid 62Granulocyte Colony-Stimulating Factor 60Antilymphocyte Serum 58Dexamethasone 57Whole-Body Irradiation 55Carmustine 54Bortezomib 45Cyclosporine 44Lenalidomide 41Methylprednisolone 40sargramostim 39Bendamustine Hydrochloride 37ibritumomab tiuxetan 34Ifosfamide 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Lymphoma × avelumab × Clear all
NCT03636503 2025-02-06

Rituximab + Immunotherapy in Follicular Lymphoma

Dana-Farber Cancer Institute

Phase 1 Terminated
24 enrolled 25 charts
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT03046953 2024-07-16

AVAIL-T

University of Birmingham

Phase 2 Completed
35 enrolled 21 charts
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡